FOCUS COLUMN
By William V. O'Connor and Kimberly R. Gosling The Supreme Court's recent opinion in Wyeth v. Levine, 2009 DJDAR 3199, has drawn significant attention over the last month. The court's decision lived up to its billing, and effectively defined the future of the federal pre-emption defense in pharmaceutical product liability cases. But industries regulated by the Food and Drug Administration are not the only ones taking note of Su...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In